Eczema: barrier first, then steroids done properly, then escalate

What eczema actually is

You are sitting on the bathroom floor at 11pm with a tub of moisturiser in one hand and a tube of hydrocortisone in the other, looking at your child’s flexures and trying to decide whether to put the steroid on or whether you’ve already used it too many times this week. The GP said use it. Someone in the eczema Facebook group said it will thin her skin. Your mum said “can’t you just moisturise more.” You have heard the words “it’s just dry skin” often enough to know it isn’t.

Eczema — properly atopic dermatitis — is not dry skin. It is a chronic relapsing inflammatory skin condition driven by two parallel problems: a structurally leaky skin barrier (a loss-of-function variant in the filaggrin gene in roughly a third of patients, plus broader barrier-lipid abnormalities in most others) and a Th2-skewed immune response with elevated IL-4, IL-13, IL-31, and TSLP doing the inflammatory work and a lot of the itch. The Australasian College of Dermatologists puts the Australian paediatric prevalence at around 1 in 5 children and roughly 1 in 10 adults — the AU figure is among the highest in the world.

The biological model matters because it tells you why “just moisturise more” is half-right and why the rest of the answer is proactive treatment of the inflammation rather than waiting for the next flare and reacting to it. The two layers — barrier and inflammation — need parallel work. That is the entire framework everything else flows from.

A. Core clinical — the AU primary-care framework

Diagnosis

Eczema is a clinical diagnosis. There is no blood test, no biopsy, no allergy panel that confirms it. The diagnostic pattern combines four features described in the modified Hanifin and Rajka criteria and echoed in the American Academy of Dermatology criteria:

• Pruritus (itch) — required
• Age-typical distribution — infants on face, scalp, and extensor surfaces; toddlers and school-age children on flexures (inside elbows, behind knees, wrists, ankles, neck, eyelids); adults often hands and head/neck
• Chronic or relapsing course
• Personal or family history of atopy — eczema, asthma, allergic rhinitis, food allergy

Severity is documented using validated tools: SCORAD, EASI, and the patient-reported POEM (Patient-Oriented Eczema Measure). Most Australian GPs don’t formally score in routine consults, but EASI and IGA matter for biologic eligibility — if your child might be heading toward dupilumab or upadacitinib, the dermatologist will need a score.

Atopic march

The pattern is recognisable: eczema in infancy, food allergy in the first year, allergic rhinitis from preschool, asthma by school age. Not every child travels the whole road, but eczema doubles the lifetime risk of the others. The ASCIA infant feeding guidelines reflect the LEAP-trial finding that early introduction of allergenic foods (peanut, egg) from around 6 months — not avoidance — actually reduces the food-allergy risk in high-risk infants. This was the opposite of advice given in the 1990s and 2000s, and it is one of the most important practical updates in paediatric allergy.

Triggers

Triggers don’t cause eczema — they tip an already-vulnerable barrier and immune system into a flare. The common ones, per Eczema Association Australasia:

• Irritants — soaps, bubble bath, fragranced washes, wool, harsh detergents
• Aeroallergens — house dust mite, pet dander, pollen (less consistent than in asthma/rhinitis)
• Sweating and heat — gym, summer, overheated bedrooms
• Infection — Staphylococcus aureus colonises around 90% of eczematous skin and superantigens drive flares
• Stress
• Hard water, chlorinated pool water in some children

Differential diagnosis

The patterns that look like eczema but aren’t, and matter to separate per eTG Dermatology:

• Seborrhoeic dermatitis — greasy yellow scale on scalp, eyebrows, nasolabial folds; cradle cap in infants
• Contact dermatitis — distribution matches the contactant (under a watch strap, around a piercing, glove cuff line); patch testing confirms
• Scabies — burrows in finger webs and wrists, itch worse at night, contact pruritus in the household
• Psoriasis — well-demarcated plaques with silvery scale, extensor distribution, nail pitting
• Tinea — annular with central clearing and a scaly leading edge; skin scrapings confirm
• Cutaneous T-cell lymphoma (mycosis fungoides) — adult with persistent atypical patches not behaving like eczema; biopsy

Two red flags worth knowing

Eczema herpeticum — sudden monomorphic clusters of small punched-out vesicles or erosions, often around the head and neck, often with fever and unwell child or adult. This is herpes simplex virus on a broken eczema canvas and it can be sight-threatening or systemically serious. It is an emergency department presentation for IV or oral aciclovir, sometimes with ophthalmology if anywhere near the eye.

Bacterial superinfection — golden crust, weeping pustules, tender lymphadenopathy, fever. Needs a skin swab and oral cephalexin or flucloxacillin per AMH. Recurrent infection warrants screening for MRSA.

B. Evidence appraisal — the treatment ladder

Step 1: emollients (the foundation)

The single most under-rated treatment in eczema. The 2017 Cochrane review by van Zuuren and colleagues of emollient use in atopic dermatitis showed a modest but consistent reduction in flare frequency and severity, reduced topical steroid requirement, and improved quality of life. The ACD and ASCIA positions both align on the practical points:

• Fragrance-free. Fragrance is the most common irritant in OTC moisturisers.
• Ointments over thick creams over lotions for moderate-to-severe eczema. Lotions are mostly water and evaporate; ointments occlude and trap water in the skin.
• Generous quantity. ASCIA’s benchmark for moderate-to-severe is roughly 250 g/week in adults and 100 g/week in children. If you are buying a 50 g tube a month, you are underdosing — most of the work happens through volume, not branding.
• Many times a day. At minimum twice; ideally every nappy change for infants, every hand wash for hand eczema.
• Apply within 3 minutes of bathing. Pat dry, don’t rub.

If the choice is one of these to start at home this week, this is the one. It is the floor under everything else.

Step 2: topical corticosteroids, done properly

This is where most of the noise lives. The Australian topical corticosteroid ladder, per eTG Dermatology and AMH:

• Mild — hydrocortisone 1% cream/ointment. Safe on face, eyelids, infant skin, flexures.
• Moderate — methylprednisolone aceponate 0.1% (Advantan); betamethasone valerate 0.02–0.05% (Betnovate ½ or Betnovate). Body, limbs, short-to-medium runs.
• Potent — mometasone 0.1% (Elocon); betamethasone valerate 0.1%. Body short-term for moderate-to-severe flares.
• Very potent — betamethasone dipropionate optimised (Diprosone OV); clobetasol 0.05% (Dermovate). Palms, soles, lichenified plaques — short courses only, dermatology involvement preferable.

The two practical concepts that separate confident steroid use from anxious underuse:

Fingertip-unit dosing. One fingertip unit (from the tip of an adult index finger to the first crease) is enough to treat an area the size of two adult palms. It is more cream than most parents instinctively use.

Proactive maintenance — the single biggest practice shift of the last decade. The Wollenberg JEADV 2018 systematic review summarised the trial evidence: applying topical steroid (or topical calcineurin inhibitor) twice weekly to previously-affected sites during good-skin periods reduces flare frequency by approximately 40% compared to reactive-only treatment. This is not continuous use of steroids — it is short, regular pulses to skin that already healed, which keeps the subclinical inflammation that drives the next flare from re-igniting. It works.

Step 3: topical calcineurin inhibitors

Steroid-sparing options for face, eyelids, and flexures — areas where chronic steroid use is more likely to cause atrophy:

• Pimecrolimus 1% (Elidel) — mild-to-moderate; lower potency.
• Tacrolimus 0.03% (Protopic) in children, 0.1% in adults — moderate-to-severe.

Both are PBS Authority. Burning or stinging in the first week is common and usually settles. The historical FDA boxed warning about a theoretical lymphoma/skin-cancer risk has not been borne out across multiple large cohort studies — the International Eczema Council considers them safe with appropriate counselling. Many GPs and dermatologists use them as the maintenance arm of proactive therapy on the face, with TCS as the rescue option for flares.

Step 4: phototherapy

Narrow-band UVB (NBUVB) two-to-three times weekly for a few months has good evidence for moderate-to-severe eczema unresponsive to topicals. Access in Australia is uneven — metropolitan dermatology clinics and some hospital outpatient departments offer it; regional access is patchy.

Step 5: systemic and biologic therapy

For severe disease that has failed an optimised topical trial, the Australian options now look very different to a decade ago. The Rubel et al. 2025 Australasian Journal of Dermatology review summarises the current PBS landscape:

• Short-course oral corticosteroids (prednisolone) — only for severe flares as a bridge, never as maintenance. Rebound on cessation is common.
• Methotrexate, ciclosporin, azathioprine — older systemic immunosuppressants, PBS Authority for severe AD, all with monitoring requirements (LFTs, FBC, blood pressure, TPMT/NUDT15 testing for azathioprine).
• Dupilumab (Dupixent) — anti-IL-4Rα monoclonal antibody, PBS Authority Required for severe AD aged 6+ since 2021, no boxed warning, conjunctivitis in ~10%.
• Tralokinumab (Adtralza) — anti-IL-13, PBS Authority for severe AD in adults. Lebrikizumab — anti-IL-13, TGA/PBS pipeline in 2025–26.
• Oral JAK inhibitors — upadacitinib (Rinvoq), abrocitinib (Cibinqo), baricitinib — fast oral onset for severe disease, PBS Authority for adults meeting criteria. They carry a TGA boxed warning covering venous thromboembolism, major cardiovascular events, and malignancy, derived largely from the older rheumatoid-arthritis population — the absolute risks in eczema patients are lower but real, and warrant baseline screening (hepatitis B/C, HIV, TB IGRA, lipids, FBC, LFTs, pregnancy) and ongoing monitoring.

The choice between dupilumab and a JAK inhibitor — when both are options — typically comes down to speed versus long-term safety profile. JAKs work faster (days to weeks) and are oral; dupilumab is an injection every two weeks with a slower onset but the cleaner long-term safety profile. That is a dermatologist conversation, not a GP one, but it helps to know the trade-off going in.

Step 6: topical JAK inhibitors

Ruxolitinib 1.5% cream (Opzelura) has FDA approval and is in TGA pipeline review for Australian listing — when AU lags, the gap is worth naming so you know what to ask about. Crisaborole (a PDE4 inhibitor) has marginal additional value over moderate-potency TCS and limited AU uptake.

C. The topical-steroid-withdrawal and steroid-phobia conversation

This is the part of the eczema conversation where the loudest voices are usually wrong on at least one side.

Topical steroid withdrawal (TSW) — sometimes called red skin syndrome or steroid addiction in lay forums — is a real but uncommon clinical phenomenon. The International Eczema Council 2021 position paper characterises it as a syndrome that can follow prolonged use of moderate-to-potent topical steroids (often on the face, often months-to-years continuous), presenting with burning sensation, bright erythema that extends beyond the original eczema territory, oedema, and a clinical course distinct from ordinary rebound. The Australasian College of Dermatologists position statement acknowledges TSW as a recognised entity while emphasising that the much more prevalent population-level problem is steroid phobia driving chronic undertreatment.

Hold both of these things at the same time. They are both true.

A subset of patients — particularly those who have used potent or very-potent topical steroids continuously on the face for extended periods without supervision — can develop TSW, and they deserve dermatology-led management. At the same time, the average Australian parent dabbing a pea of hydrocortisone on a flexural patch twice a week is in approximately zero TSW risk and far more likely to underuse than overuse. The Eczema Association Australasia have spoken to both realities.

The integrative reframe sits underneath all of this: optimise the barrier first so the inflammation burden drops naturally. Adequate fragrance-free emollient at 250 g/week. Soap-free wash. Treat infection when present. Reduce known irritants (hot showers, harsh detergents, wool against skin). Bleach baths for recurrent staphylococcal colonisation per Sydney Children’s Hospitals Network protocol — 1/4 cup household bleach in a full bathtub, 10 minutes, twice weekly. As the barrier improves, steroid burden naturally falls. That is the actual goal — not zero steroid by ideology, but appropriate steroid by physiology.

If you are worried about TSW in yourself or your child, the path is the same one as for severe persistent eczema: dermatology review. Stopping appropriate steroid based on an online thread, in a child whose skin is actively inflamed, very reliably makes things worse before it makes them better.

D. Australian operations — the system bits that matter

PBS biologics and JAK inhibitors. Dupilumab for severe AD age 6+, upadacitinib and abrocitinib for severe AD in adults, and tralokinumab for severe AD in adults are all PBS Authority Required. The eligibility threshold is typically severe disease (EASI and IGA above defined cut-offs) plus documented failure of an adequate trial of optimised conventional treatment (topical and/or systemic). The application is almost always initiated by a dermatologist.

MBS chronic-care infrastructure. Moderate-to-severe eczema with atopic comorbidity (asthma, allergic rhinitis, mental health impact from sleep deprivation and visible disease) often qualifies for a GP Chronic Condition Management Plan — MBS items 965/967 — giving access to five subsidised allied-health sessions per calendar year (psychologist via Better Access, dietitian if there is a confirmed food allergy, occupational-therapy input for hand eczema in some cases). A Mental Health Care Plan (MBS items 2715/2717) is genuinely useful in moderate-to-severe eczema — sleep loss, body-image distress, and adolescent psychological impact are well-documented, not exotic.

Telehealth. Eczema is well-suited to telehealth review where the existing-relationship 12-month rule is met — photographic review and prescription renewal can avoid travel for stable patients.

Paediatric dermatology access. Public paediatric dermatology waitlists in many Australian regions are months long. The practical pattern: GP-led management of the barrier and topical-steroid plan with an ASCIA Eczema Action Plan in writing, while a referral runs in parallel. Severe cases with biologic candidacy benefit from earlier dermatology engagement; mild-to-moderate cases are GP-manageable.

(MBS / PBS items verified 2026-05-18 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

E. Special populations

Infants. Face-friendly topical steroids only — hydrocortisone 1% as first line, methylprednisolone aceponate 0.1% (Advantan) for moderate face/scalp flares short-course under GP supervision. Bleach baths per the Sydney Children’s Hospitals Network fact sheet are reasonable for recurrent infection from around 6 months. Food allergy screening only with a specific clinical pattern (immediate reaction to a specific food) — not as a routine eczema screen. ASCIA’s early introduction guidance — peanut, egg from around 6 months in high-risk infants — actively reduces food allergy risk.

Pregnancy. Emollients without restriction. Mild and moderate topical corticosteroids for limited durations are considered safe per AMH; avoid very potent steroids over large body surface areas. Phototherapy with NBUVB is safe. Avoid methotrexate (teratogenic) and JAK inhibitors. Dupilumab has limited but reassuring emerging safety data — case-by-case with obstetric and dermatology input.

Older adults. Xerotic eczema (asteatotic eczema, “winter eczema”) on shins and lower legs is common and often misidentified as the same disease as childhood atopic eczema. The barrier-first principle still holds — generous emollient, soap-free wash, ointment-based moisturiser, mild-to-moderate topical steroid for the inflamed patches — but the diagnostic frame is different and venous insufficiency or contact dermatitis needs to be considered.

When to escalate or refer to dermatology

• Severe eczema failing optimised topical therapy after a fair trial (typically 8–12 weeks of adequate emollient + appropriate steroid ladder + proactive maintenance)
• Suspected eczema herpeticum — urgent, same-day
• Suspected cutaneous T-cell lymphoma masquerading as eczema in an adult with atypical persistent patches
• Biologic or oral-JAK eligibility assessment
• Paediatric severe atopic dermatitis with growth failure, severe sleep loss, or significant family distress
• Suspected underlying immunodeficiency (recurrent severe infections beyond the eczema itself)
• Concerns about possible topical steroid withdrawal — dermatology-led
• Suspected contact dermatitis component needing patch testing

What this article is and is not

This is general health information drawn from current Australian primary-care guidelines — Therapeutic Guidelines, AMH, NPS MedicineWise, ASCIA, the Australasian College of Dermatologists, the Eczema Association Australasia — and the major dermatology trials. It is not personal medical advice, it does not create a doctor–patient relationship, and eczema is a chronic relapsing condition rather than something curable — so any framing that promises “cure your eczema in 30 days” is misleading regardless of who says it. Specific treatment decisions, dose adjustments, and biologic eligibility belong with your own GP, paediatrician, or dermatologist.

For Australian consumer-friendly sources: Eczema Association Australasia, HealthDirect — Eczema, Better Health Channel, ASCIA, Australasian College of Dermatologists patient information.

For acute mental-health crisis: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. ASCIA — Eczema action plan
2. Australasian College of Dermatologists
3. Therapeutic Guidelines (eTG) — Dermatology: Eczema
4. Australian Medicines Handbook
5. Eczema Association of Australasia
6. PBS — dupilumab, tralokinumab, upadacitinib, abrocitinib (Authority Required for severe AD)
7. Rubel et al. — Targeted systemic therapies for atopic dermatitis in Australia (AJD 2025)
8. Wollenberg et al. — Proactive therapy in atopic dermatitis (JEADV 2018)
9. van Zuuren et al. — Emollients for atopic dermatitis (Cochrane 2017)
10. International Eczema Council — position on topical corticosteroid withdrawal
11. Sydney Children’s Hospitals Network — bleach bath protocol
12. American Academy of Dermatology — atopic dermatitis criteria (international, used when AU criteria silent on specific subpoints)
13. MBS Online — items 965, 967, 2715, 2717, 69300
14. TGA — JAK inhibitor boxed warning, ruxolitinib topical pipeline status
15. HealthDirect — Eczema
16. Better Health Channel — Eczema